https://www.pharmaradar360.com/article/k-taka-fda-cancels-16-drug-licences-of-retailers-wholesalers-c3da9512d4ad2b56PharmaRadar360en2026-09-20T16:19:28.000ZK'taka FDA cancels 16 drug licences of retailers, wholesalershttps://www.pharmaradar360.com/article/spurious-drug-racket-busted-at-bidadi-farmhouse-rs-5-crore-stock-seized-37c1c944ca0872f9PharmaRadar360en2026-09-20T16:13:00.000ZSpurious drug racket busted at Bidadi farmhouse, Rs 5 crore stock seizedhttps://www.pharmaradar360.com/article/india-s-biotech-start-ups-need-patient-capital-to-drive-novel-drug-innovation-in-7b639daf4e308b1aPharmaRadar360en2026-09-20T16:03:20.000ZIndia’s biotech start-ups need patient capital to drive novel drug innovation, industry leaders sayhttps://www.pharmaradar360.com/article/cheap-drugs-fake-labels-non-functional-qr-codes-karnataka-fda-cancels-16-licence-30805af09704bb40PharmaRadar360en2026-09-20T15:46:00.000ZCheap drugs, fake labels, non-functional QR codes: Karnataka FDA cancels 16 licences of retailers, wholeshttps://www.pharmaradar360.com/article/karnataka-busts-fake-drug-racket-suspends-license-of-pfizer-depot-7-other-firms-5a01456374a081c9PharmaRadar360en2026-09-20T15:39:20.000ZKarnataka busts fake drug racket, suspends license of Pfizer depot, 7 other firmshttps://www.pharmaradar360.com/article/when-the-trial-fails-was-it-the-drug-or-the-design-7d9fc4711d67aecdPharmaRadar360en2026-09-20T15:28:29.000ZWhen the Trial Fails, Was It the Drug or the Design?https://www.pharmaradar360.com/article/fda-cancels-16-suspends-eight-drug-licences-in-karnataka-india-news-ba30705170e35c28PharmaRadar360en2026-09-20T15:25:26.000ZFDA cancels 16, suspends eight drug licences in Karnataka | India Newshttps://www.pharmaradar360.com/article/sartorius-stedim-stock-holds-steady-as-investors-digest-recent-results-357e977aebe6ec21PharmaRadar360en2026-09-20T15:08:26.000ZSartorius Stedim stock holds steady as investors digest recent resultshttps://www.pharmaradar360.com/article/study-finds-no-neurodevelopmental-risk-in-prenatal-covid-19-except-speech-60978aa7141468f4PharmaRadar360en2026-09-20T15:06:40.000ZStudy Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except Speechhttps://www.pharmaradar360.com/article/abbvie-s-bet-on-biology-why-one-modality-is-never-enough-in-lung-cancer-22ddcff0c7b1d6dePharmaRadar360en2026-09-20T14:58:33.000ZAbbVie’s Bet on Biology: Why One Modality Is Never Enough in Lung Cancerhttps://www.pharmaradar360.com/article/fake-drug-racket-case-why-did-karnataka-fda-take-action-against-pfizer-and-other-c891e75d1209a28ePharmaRadar360en2026-09-20T14:47:26.000ZFake drug racket case: Why did Karnataka FDA take action against Pfizer and other pharmacy establishments?https://www.pharmaradar360.com/article/retension-pharmaceuticals-trex-bio-file-for-us-ipo-as-biotech-momentum-continues-3e00c4b5d346cd8cPharmaRadar360en2026-09-20T14:41:31.000ZRetension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continueshttps://www.pharmaradar360.com/article/karnataka-16-licences-cancelled-over-suspected-fake-drug-supply-0e40f8f1294379fePharmaRadar360en2026-09-20T14:36:39.000ZKarnataka: 16 licences cancelled over suspected fake drug supplyhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-holds-near-fair-value-as-valuation-debate-int-4a13daa556aa57dePharmaRadar360en2026-09-20T14:28:16.000ZWest Pharmaceutical Services stock holds near fair value as valuation debate intensifieshttps://www.pharmaradar360.com/article/what-is-drawing-attention-to-west-pharmaceutical-services-wst-92b5c124882ba4d9PharmaRadar360en2026-09-20T14:07:44.000ZWhat Is Drawing Attention To West Pharmaceutical Services (WST)?https://www.pharmaradar360.com/article/accelerating-digital-transformation-in-the-pharmaceutical-sector-61a20ba6a4cf5dbbPharmaRadar360en2026-09-20T14:06:51.000ZAccelerating digital transformation in the pharmaceutical sectorhttps://www.pharmaradar360.com/article/pharmaceutical-society-calls-for-stronger-drug-regulation-f2db6216a77cc7afPharmaRadar360en2026-09-20T14:04:22.000ZPharmaceutical Society Calls for Stronger Drug Regulationhttps://www.pharmaradar360.com/article/la-biotech-firm-innata-bio-moves-headquarters-to-philadelphia-s-lilly-gateway-la-c364a610699ace50PharmaRadar360en2026-09-20T14:00:00.000ZLA Biotech Firm Innata Bio Moves Headquarters to Philadelphia’s Lilly Gateway Labshttps://www.pharmaradar360.com/article/karnataka-fda-cancels-16-pharmacy-licences-over-spurious-drug-racket-f06b08fa08cf993bPharmaRadar360en2026-09-20T13:57:17.000ZKarnataka FDA cancels 16 pharmacy licences over spurious drug rackethttps://www.pharmaradar360.com/article/fake-drugs-karnataka-cancels-16-licenses-suspends-8-including-that-of-pfizer-dep-72248dc68285db68PharmaRadar360en2026-09-20T13:56:00.000ZFake drugs: Karnataka cancels 16 licenses, suspends 8 including that of Pfizer depothttps://www.pharmaradar360.com/article/spurious-drug-racket-busted-at-farmhouse-in-karnataka-s-bidadi-24-pharma-licence-55071d8965d7b532PharmaRadar360en2026-09-20T13:51:57.000ZSpurious Drug Racket Busted At Farmhouse In Karnataka's Bidadi, 24 Pharma Licences Face Actionhttps://www.pharmaradar360.com/article/is-ultragenyx-pharmaceutical-rare-cheap-on-fayuvi-fda-approval-ba65c38fdef312f2PharmaRadar360en2026-09-20T13:44:01.000ZIs Ultragenyx Pharmaceutical (RARE) Cheap On FAYUVI FDA Approval?https://www.pharmaradar360.com/article/fda-warned-covid-vaccine-safety-tool-was-broken-then-silenced-doctor-who-told-th-f38dbda48e4ec923PharmaRadar360en2026-09-20T13:20:08.000ZFDA Warned COVID Vaccine Safety Tool Was Broken, Then Silenced Doctor Who Told Them, Report Findshttps://www.pharmaradar360.com/article/gh-research-buy-gh001-trd-advancement-presses-on-and-expansion-opportunities-325030f39a18e63ePharmaRadar360en2026-09-20T13:19:07.000ZGH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunitieshttps://www.pharmaradar360.com/article/karnataka-fake-drug-racket-16-pharmacy-licences-cancelled-action-against-pfizer-bf44254334094df4PharmaRadar360en2026-09-20T13:03:45.000ZKarnataka Fake Drug Racket: 16 Pharmacy Licences Cancelled, Action Against Pfizer C&F Depothttps://www.pharmaradar360.com/article/frazier-life-sciences-raises-more-than-1-1-billion-for-public-biotech-fund-bring-8a89e2c526ed56c6PharmaRadar360en2026-09-20T12:50:43.000ZFrazier Life Sciences Raises More Than $1.1 Billion For Public Biotech Fund, Bringing Commitments To $2.8 Billionhttps://www.pharmaradar360.com/article/pharmacists-protest-expansion-of-non-face-to-face-care-and-medication-delivery-2d8c26b6369332e5PharmaRadar360en2026-09-20T11:41:37.000ZPharmacists Protest Expansion of Non-Face-to-Face Care and Medication Deliveryhttps://www.pharmaradar360.com/article/bytedance-s-favored-child-unveils-the-capital-game-of-the-ai-pharmaceutical-indu-604a2f26528da009PharmaRadar360en2026-09-20T11:13:46.000ZByteDance's Favored Child Unveils the Capital Game of the AI Pharmaceutical Industryhttps://www.pharmaradar360.com/article/teva-price-today-teva-pharmaceutical-industries-limited-stock-price-quote-chart-8ccacc4f83865af8PharmaRadar360en2026-09-20T11:07:14.000ZTEVA Price Today: Teva Pharmaceutical Industries Limited Stock Price, Quote & Chart | MEXChttps://www.pharmaradar360.com/article/hospital-pharmacies-drug-distributors-come-under-fda-scanner-8b044166b5548d2aPharmaRadar360en2026-09-20T10:32:44.000ZHospital pharmacies, drug distributors come under FDA scannerhttps://www.pharmaradar360.com/article/2-wall-street-analysts-think-argenx-can-soar-more-than-40-here-s-why-they-re-rig-f513a4249132800fPharmaRadar360en2026-09-20T10:31:39.000Z2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.https://www.pharmaradar360.com/article/cue-biopharma-announces-positive-topline-results-from-cue-221-phase-2-study-in-c-8b819eb2bbb81bc1PharmaRadar360en2026-09-20T10:17:30.000ZCue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticariahttps://www.pharmaradar360.com/article/multilayer-composite-filter-cartridges-market-forecast-to-2035-driven-by-tighten-48c160638f5d9a44PharmaRadar360en2026-09-20T10:16:12.000ZMultilayer Composite Filter Cartridges Market Forecast to 2035, Driven by Tightening Quality Standards in Food and Pharmaceutical Processinghttps://www.pharmaradar360.com/article/2-wall-street-analysts-think-argenx-can-soar-more-than-40-here-s-why-they-re-rig-9739b0ac2a71928bPharmaRadar360en2026-09-20T10:12:51.000Z2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.https://www.pharmaradar360.com/article/nashik-fda-seizes-food-stock-worth-48-81-lakh-during-festive-inspection-drive-732b4a4f83191eb5PharmaRadar360en2026-09-20T10:11:00.000ZNashik: FDA Seizes Food Stock Worth ₹48.81 Lakh During Festive Inspection Drivehttps://www.pharmaradar360.com/article/cue-biopharma-reports-positive-phase-2-topline-results-for-cue-221-in-chronic-sp-01dd38d09c11110dPharmaRadar360en2026-09-20T10:10:00.000ZCue Biopharma Reports Positive Phase 2 Topline Results for CUE-221 in Chronic Spontaneous Urticariahttps://www.pharmaradar360.com/article/novartis-stock-falls-as-clinical-setbacks-weigh-despite-cosentyx-eu-boost-ae4da72e806448abPharmaRadar360en2026-09-20T09:27:48.000ZNovartis stock falls as clinical setbacks weigh despite Cosentyx EU boosthttps://www.pharmaradar360.com/article/the-nih-funding-crisis-that-could-reshape-biotech-for-years-to-come-b62b5f7bdd7a60dePharmaRadar360en2026-09-20T09:18:35.000ZThe NIH funding crisis that could reshape biotech for years to comehttps://www.pharmaradar360.com/article/teva-price-today-teva-pharmaceutical-industries-limited-stock-price-quote-chart-8ba310a09d4d3d79PharmaRadar360en2026-09-20T09:04:43.000ZTEVA Price Today: Teva Pharmaceutical Industries Limited Stock Price, Quote & Chart | MEXChttps://www.pharmaradar360.com/article/cmps-stock-clocks-muted-gains-but-analysts-back-psychedelic-drug-s-durability-ah-6a4a3cae17e5d82cPharmaRadar360en2026-09-20T08:43:11.000ZCMPS Stock Clocks Muted Gains But Analysts Back Psychedelic Drug’s Durability Ahead Of FDA Filinghttps://www.pharmaradar360.com/article/kathmandu-pharmaceutical-association-urges-legal-operation-of-pharmacies-3039b3bd045c8d73PharmaRadar360en2026-09-20T08:30:59.000ZKathmandu Pharmaceutical Association Urges Legal Operation of Pharmacieshttps://www.pharmaradar360.com/article/west-pharmaceutical-services-stock-holds-a-moderate-buy-rating-f8faf2c1ee001e7ePharmaRadar360en2026-09-20T08:25:50.000ZWest Pharmaceutical Services stock holds a Moderate Buy ratinghttps://www.pharmaradar360.com/article/ingrid-zhang-excited-to-advance-legend-biotech-s-mission-and-transform-patient-o-c737cea7423c9618PharmaRadar360en2026-09-20T07:17:18.000ZIngrid Zhang։ Excited to Advance Legend Biotech’s Mission and Transform Patient Outcomeshttps://www.pharmaradar360.com/article/liver-injury-fda-warning-for-tavneos-patients-0a86acc18b6c86dbPharmaRadar360en2026-09-20T06:47:40.000ZLiver Injury FDA Warning for Tavneos Patientshttps://www.pharmaradar360.com/article/we-need-to-balance-business-livelihoods-with-public-health-says-maharashtra-fda-cadd731e9a9abe0cPharmaRadar360en2026-09-20T05:25:00.000Z‘We need to balance business & livelihoods with public health,' says Maharashtra FDA chief Tukaram Mundhehttps://www.pharmaradar360.com/article/hanmi-pharmaceutical-tightens-china-unit-controls-after-receivables-risk-chosunb-99641c81ca75d958PharmaRadar360en2026-09-20T05:09:00.000ZHanmi Pharmaceutical tightens China unit controls after receivables risk - CHOSUNBIZhttps://www.pharmaradar360.com/article/mumbai-cafe-visited-by-tom-holland-matt-damon-and-christopher-nolan-loses-licenc-66f4b9289871ea70PharmaRadar360en2026-09-20T04:45:03.000ZMumbai café visited by Tom Holland, Matt Damon and Christopher Nolan loses licence over hygiene violationshttps://www.pharmaradar360.com/article/rest-of-asia-pacific-process-analytical-technology-market-size-share-trends-grow-63a8de689d51c9aaPharmaRadar360en2026-09-20T04:22:02.000Zrest-of-asia-pacific Process Analytical Technology Market Size, Share,Trends, Growth Analysis Report, 2031https://www.pharmaradar360.com/article/the-truth-about-msg-1968-prank-letter-that-started-a-50-decade-myth-bdfbbbdceed9e3fbPharmaRadar360en2026-09-20T04:00:25.000ZThe truth about MSG: 1968 prank letter that started a 50-decade mythhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-could-be-10-undervalued-on-glp-1-and-annex-1-de-450d25329be4d6e4PharmaRadar360en2026-09-20T03:54:24.000ZWest Pharmaceutical Services (WST) Could Be 10% Undervalued On GLP 1 And Annex 1 Demandhttps://www.pharmaradar360.com/article/kaist-develops-new-catalyst-technology-for-complex-pharmaceutical-synthesis-c3c0f350dea7f0f8PharmaRadar360en2026-09-20T03:00:00.000ZKAIST develops new catalyst technology for complex pharmaceutical synthesishttps://www.pharmaradar360.com/article/croda-opens-global-biotech-r-d-centre-in-uk-185f240d9d5e36c2PharmaRadar360en2026-09-20T02:49:34.000ZCroda opens global biotech R&D centre in UKhttps://www.pharmaradar360.com/article/anthropic-builds-biology-lab-in-san-francisco-to-accelerate-drug-discovery-d780d94f7dedf9a9PharmaRadar360en2026-09-20T02:39:36.000ZAnthropic Builds Biology Lab in San Francisco to Accelerate Drug Discoveryhttps://www.pharmaradar360.com/article/csafe-launches-silverskin-re-pmc-reusable-thermal-cover-for-pharmaceutical-air-f-9773a41f94db98a1PharmaRadar360en2026-09-20T02:35:25.000ZCSafe launches Silverskin RE PMC reusable thermal cover for pharmaceutical air freighthttps://www.pharmaradar360.com/article/china-declares-bid-for-global-drug-innovation-dominance-by-2030-7e1f328ec4984e65PharmaRadar360en2026-09-20T01:59:25.000ZChina declares bid for global drug innovation dominance by 2030https://www.pharmaradar360.com/article/anthropic-opens-san-francisco-biology-lab-to-speed-preclinical-drug-r-d-chosunbi-749840280cf686cdPharmaRadar360en2026-09-20T01:47:00.000ZAnthropic opens San Francisco biology lab to speed preclinical drug R&D - CHOSUNBIZhttps://www.pharmaradar360.com/article/pharmaceutical-cosmetics-with-high-function-and-high-content-ingredients-are-eme-d5bdb04201e31bebPharmaRadar360en2026-09-20T01:33:30.000ZPharmaceutical cosmetics with high-function and high-content ingredients are emerging as a new beaut..https://www.pharmaradar360.com/article/dr-congo-expands-ebola-vaccination-to-ituri-over-3-700-vaccinated-047055f5d7c00cadPharmaRadar360en2026-09-20T01:23:15.000ZDr Congo expands Ebola vaccination to Ituri, over 3,700 vaccinatedhttps://www.pharmaradar360.com/article/raid-on-abl-bio-shakes-confidence-in-k-biotech-sector-61fe57bbfb60db99PharmaRadar360en2026-09-20T00:39:52.000ZRaid on ABL Bio shakes confidence in K-biotech sectorhttps://www.pharmaradar360.com/article/stanford-s-virtual-biotech-turns-37-000-ai-agents-into-a-drug-discovery-factory-6211ed771f1838afPharmaRadar360en2026-09-20T00:20:27.000ZStanford's Virtual Biotech turns 37,000 AI agents into a drug-discovery factoryhttps://www.pharmaradar360.com/article/biotech-stocks-need-a-shot-in-the-arm-after-brutal-july-could-astrazeneca-bristo-0c28c1010a46e800PharmaRadar360en2026-09-20T00:06:37.000ZBiotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-78dc45452df57b9dPharmaRadar360en2026-09-20T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-d73537319e9e4cabPharmaRadar360en2026-09-20T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-b01a81a06fbe494bPharmaRadar360en2026-09-20T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-10852d8b9e46ac9bPharmaRadar360en2026-09-20T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-3543142cb2e38220PharmaRadar360en2026-09-20T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-f4b73a83036d3dffPharmaRadar360en2026-09-20T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-9d8e41ab9dbc589cPharmaRadar360en2026-09-20T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-97e61d5508abfdd8PharmaRadar360en2026-09-20T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-fc6b0191693df25ePharmaRadar360en2026-09-20T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-713987d111c86040PharmaRadar360en2026-09-20T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-e44c9a5b90af42d0PharmaRadar360en2026-09-20T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-8172ea7ddb145237PharmaRadar360en2026-09-20T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-0bef7b0d07ffdca6PharmaRadar360en2026-09-20T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-d8234cbca452c7fdPharmaRadar360en2026-09-20T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/comparative-evaluation-of-two-commercially-available-topical-gels-as-adjuncts-to-3e242aaa23a99262PharmaRadar360en2026-09-20T00:00:00.000ZComparative Evaluation of Two Commercially Available Topical Gels As Adjuncts to Scaling and Root Planing for Gingival Inflammation: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/clinical-outcomes-and-inflammatory-biomarker-changes-after-intravenous-ketamine-9ffa70defb76dc3aPharmaRadar360en2026-09-20T00:00:00.000ZClinical Outcomes and Inflammatory Biomarker Changes After Intravenous Ketamine-Lidocaine Infusion in Refractory Neuropathic Pain: A Prospective Observational Pilot Studyhttps://www.pharmaradar360.com/article/clinical-dermoscopic-and-histopathological-correlation-of-pigmented-skin-lesions-c6145a7d2a81fae7PharmaRadar360en2026-09-20T00:00:00.000ZClinical, Dermoscopic, and Histopathological Correlation of Pigmented Skin Lesions at a Tertiary Care Dermatology Centerhttps://www.pharmaradar360.com/article/dynamic-interactions-between-tumor-associated-macrophages-and-breast-cancer-cell-b1c9964f3d00bdfcPharmaRadar360en2026-09-20T00:00:00.000ZDynamic Interactions Between Tumor-Associated Macrophages and Breast Cancer Cells from a Spatiotemporal Perspective: Mechanisms, Therapeutic Targets, and Prospects for Clinical Translationhttps://www.pharmaradar360.com/article/lt-b-gt-drug-repurposing-potential-of-natural-products-molecular-targets-pharmac-3b6b1335f539e8b8PharmaRadar360en2026-09-20T00:00:00.000Z&lt;b&gt;Drug Repurposing Potential of Natural Products: Molecular Targets, Pharmacological Profiles, and Precision Therapeutic Strategies: A Narrative Review &lt;/b&gt;https://www.pharmaradar360.com/article/concurrent-use-of-herbal-medicines-and-prescription-drugs-and-potential-herb-dru-1b19d6e302bf62e7PharmaRadar360en2026-09-20T00:00:00.000ZConcurrent Use of Herbal Medicines and Prescription Drugs and Potential Herb-Drug Interactions: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/vital-pulp-therapy-contemporary-concepts-materials-and-clinical-outcomes-a-narra-39cd8515ac92c91ePharmaRadar360en2026-09-20T00:00:00.000ZVital Pulp Therapy: Contemporary Concepts, Materials, and Clinical Outcomes — A Narrative Reviewhttps://www.pharmaradar360.com/article/integrating-traditional-endodontics-with-vital-pulp-therapy-a-contemporary-revie-0c1584bd96cb3876PharmaRadar360en2026-09-20T00:00:00.000ZIntegrating Traditional Endodontics with Vital Pulp Therapy: A Contemporary Review of Concepts, Materials, and Clinical Decision-Makinghttps://www.pharmaradar360.com/article/lt-b-gt-pelvic-inflammatory-disease-pid-among-women-of-reproductive-and-perimeno-08a675571af30cfdPharmaRadar360en2026-09-20T00:00:00.000Z&lt;b&gt;Pelvic Inflammatory Disease (PID) Among Women of Reproductive and Perimenopausal Age in Delta State, Nigeria: Prevalence, Symptoms, Risk Factors, Awareness, and Health-Seeking Behaviours; A Cross-Sectional Study&lt;/b&gt;https://www.pharmaradar360.com/article/7-clinical-significance-and-imaging-techniques-of-weight-bearing-radiography-6b4f8857f8b4dbedPharmaRadar360en2026-09-20T00:00:00.000Z7. Clinical Significance and Imaging Techniques of Weight-Bearing Radiographyhttps://www.pharmaradar360.com/article/clinical-profile-and-outcomes-of-patients-without-an-attendant-admitted-to-the-e-0c9a353a1ee8ffebPharmaRadar360en2026-09-20T00:00:00.000ZClinical profile and outcomes of patients without an attendant admitted to the emergency departments of selected governmental hospitals in Addis Ababa, Ethiopiahttps://www.pharmaradar360.com/article/clinical-profile-and-outcome-of-louse-borne-relapsing-fever-among-patients-seen-2033a2162f917eb0PharmaRadar360en2026-09-20T00:00:00.000ZClinical Profile and Outcome of Louse-Borne Relapsing Fever Among Patients Seen at Zewditu Memorial Hospital and Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Cross-Sectional Studyhttps://www.pharmaradar360.com/article/microwave-breast-imaging-a-review-of-clinical-potential-and-technological-advanc-5e9290688094301cPharmaRadar360en2026-09-20T00:00:00.000ZMicrowave breast imaging: A review of clinical potential and technological advanceshttps://www.pharmaradar360.com/article/artificial-intelligence-in-ophthalmology-from-diagnostic-accuracy-to-clinical-ap-1fd69aa3ee10e722PharmaRadar360en2026-09-20T00:00:00.000ZArtificial intelligence in ophthalmology: From diagnostic accuracy to clinical applicationhttps://www.pharmaradar360.com/article/culture-conversion-and-drug-susceptibility-in-drug-resistant-pulmonary-tuberculo-760f453f0ef28ed1PharmaRadar360en2026-09-20T00:00:00.000ZCulture conversion and drug susceptibility in drug-resistant pulmonary tuberculosis with type 2 diabetes mellitus on oral regimenshttps://www.pharmaradar360.com/article/bone-specific-alkaline-phosphatase-as-a-marker-of-bone-formation-clinical-and-im-bb8c60f2f1a2bbf9PharmaRadar360en2026-09-20T00:00:00.000ZBone-specific alkaline phosphatase as a marker of bone formation: Clinical and imaging correlateshttps://www.pharmaradar360.com/article/precision-medicine-in-diffuse-large-b-cell-lymphoma-integrating-molecular-biomar-e12408836930ea28PharmaRadar360en2026-09-20T00:00:00.000ZPrecision medicine in diffuse large B-cell lymphoma: Integrating molecular biomarkers, targeted therapies, and prognostic toolshttps://www.pharmaradar360.com/article/evolving-molecular-epidemiology-and-antimicrobial-resistance-of-streptococcus-ag-f4af1e23a3a99148PharmaRadar360en2026-09-20T00:00:00.000ZEvolving molecular epidemiology and antimicrobial resistance of Streptococcus agalactiae in South Korea and East Asia: a narrative reviewhttps://www.pharmaradar360.com/article/molecular-mechanisms-epidemiology-and-clinical-implications-of-macrolide-resista-4b7c7553c8d37028PharmaRadar360en2026-09-20T00:00:00.000ZMolecular mechanisms, epidemiology, and clinical implications of macrolide resistance in group A Streptococcus: a narrative reviewhttps://www.pharmaradar360.com/article/macrolide-resistant-mycoplasma-pneumoniae-laboratory-diagnosis-and-epidemiology-00c61260210edeafPharmaRadar360en2026-09-20T00:00:00.000ZMacrolide-resistant Mycoplasma pneumoniae: laboratory diagnosis and epidemiologyhttps://www.pharmaradar360.com/article/generative-ai-for-drug-discovery-gpt-2-and-lstm-based-models-for-designing-egfr-be331195ce66e861PharmaRadar360en2026-09-20T00:00:00.000ZGenerative AI for Drug Discovery: GPT-2 and LSTM-Based Models for Designing EGFR Inhibitorshttps://www.pharmaradar360.com/article/a-critical-examination-of-the-principle-of-proportionality-in-indonesian-food-an-fcf1c94dc7be344cPharmaRadar360en2026-09-20T00:00:00.000ZA Critical Examination of the Principle of Proportionality in Indonesian Food and Drug Authority Regulation Number 25 of 2025: Cosmetic Ingredient Bans and Transition Periodshttps://www.pharmaradar360.com/article/mesenchymal-stem-cells-as-a-therapeutic-treatment-for-osteogenesis-imperfecta-cu-e072c0f354a4ea8dPharmaRadar360en2026-09-20T00:00:00.000ZMesenchymal Stem Cells as a Therapeutic Treatment for Osteogenesis Imperfecta: Current Understanding Through Clinical Trialshttps://www.pharmaradar360.com/article/association-of-serum-anion-gap-and-angiographic-severity-of-coronary-artery-dise-7fec8997e4390d0dPharmaRadar360en2026-09-20T00:00:00.000ZAssociation of Serum Anion Gap and Angiographic Severity of Coronary Artery Disease by Gensini Score in Patients with Acute Coronary Syndromehttps://www.pharmaradar360.com/article/assessing-the-severity-and-persistence-of-depressive-symptoms-in-patients-with-a-cafa3d208182786fPharmaRadar360en2026-09-20T00:00:00.000ZAssessing the Severity and Persistence of Depressive Symptoms in Patients with Acute Coronary Syndromehttps://www.pharmaradar360.com/article/from-imaging-to-intervention-insights-from-nuclear-imagingin-revascularization-s-42a53e36ac487ef0PharmaRadar360en2026-09-20T00:00:00.000ZFrom Imaging to Intervention: Insights from Nuclear Imagingin Revascularization Strategies for Coronary Artery Diseasehttps://www.pharmaradar360.com/article/pop-culture-psychopathy-how-media-exposure-affects-laypersons-recognition-of-cli-105ad74b143a54eaPharmaRadar360en2026-09-20T00:00:00.000ZPop-Culture Psychopathy: How Media Exposure Affects Laypersons’ Recognition of Clinical Psychopathic Traitshttps://www.pharmaradar360.com/article/the-generalizability-gap-in-aortic-stenosis-analysis-of-87-clinical-trials-vs-re-462f7fdf6223115cPharmaRadar360en2026-09-20T00:00:00.000ZThe Generalizability Gap in Aortic Stenosis: Analysis of 87 Clinical Trials vs. Real-World Practicehttps://www.pharmaradar360.com/article/premature-children-s-developmental-outcomes-following-a-cognitive-behavioral-the-5c454b005b379d8bPharmaRadar360en2026-09-20T00:00:00.000ZPremature Children’s Developmental Outcomes Following a Cognitive Behavioral Therapy Intervention Targeting Parental Perceptions of Child Vulnerability: An Exploratory Longitudinal Follow-up of the PreVNT Randomized Trialhttps://www.pharmaradar360.com/article/the-effect-of-smart-water-flosser-on-oral-health-in-children-aged-3-6-years-a-ra-b063cc8927bd0054PharmaRadar360en2026-09-20T00:00:00.000ZThe Effect of Smart Water Flosser on Oral Health in Children Aged 3-6 Years: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/the-effect-of-hd-tdcs-with-task-oriented-upper-limb-training-after-stroke-a-rand-6f59653cb40a0544PharmaRadar360en2026-09-20T00:00:00.000ZThe Effect of HD-tDCS With Task-Oriented Upper-Limb Training After Stroke: A Randomized Sham-Controlled Trialhttps://www.pharmaradar360.com/article/pleomorphic-adenoma-of-the-upper-lip-a-case-report-with-histopathological-and-cl-792dd50f5fa1863ePharmaRadar360en2026-09-20T00:00:00.000ZPleomorphic Adenoma of the Upper Lip: A Case Report with Histopathological and Clinical Correlationhttps://www.pharmaradar360.com/article/charlson-comorbidity-index-in-predicting-postoperative-complications-and-long-te-4da7c00fc6503664PharmaRadar360en2026-09-20T00:00:00.000ZCharlson comorbidity index in predicting postoperative complications and long-term outcomes after esophagectomy: A multicenter retrospective studyhttps://www.pharmaradar360.com/article/diagnostic-value-of-tissue-mrna-and-microrna-expression-profiles-for-differentia-2bddcda45b23b852PharmaRadar360en2026-09-20T00:00:00.000ZDiagnostic value of tissue mRNA and microRNA expression profiles for differentiating pancreatic cancer from chronic pancreatitis: A pilot studyhttps://www.pharmaradar360.com/article/comparison-of-functional-and-clinical-outcomes-following-intramedullary-nailing-6fb028cd952f9fd5PharmaRadar360en2026-09-20T00:00:00.000ZComparison of Functional and Clinical Outcomes Following Intramedullary Nailing versus Plate Fixation for Humeral Shaft Fractures: A Prospective Studyhttps://www.pharmaradar360.com/article/a-retrospective-clinical-analysis-of-amir-kabir-s-migraine-a-microhistorical-app-dad5b514d33c37f9PharmaRadar360en2026-09-20T00:00:00.000ZA retrospective clinical analysis of Amir Kabir’s migraine: A microhistorical approach to reinterpreting Qajar political historyhttps://www.pharmaradar360.com/article/online-education-program-communication-effectiveness-and-communication-self-effi-c61939f87ae542acPharmaRadar360en2026-09-20T00:00:00.000ZOnline education program, communication effectiveness, and communication self-efficacy among family caregivers of people with post-stroke aphasia: A non-randomized clinical trialhttps://www.pharmaradar360.com/article/tarlatamab-treatment-for-metastatic-small-cell-neuroendocrine-carcinoma-of-the-b-665d1ff5d5c710e5PharmaRadar360en2026-09-20T00:00:00.000ZTarlatamab Treatment for Metastatic Small Cell Neuroendocrine Carcinoma of the Breast: A Case Reporthttps://www.pharmaradar360.com/article/unexpected-lack-of-efficacy-of-liposomal-encapsulated-daunorubicin-cytarabine-in-f3201b034cab8a05PharmaRadar360en2026-09-20T00:00:00.000ZUnexpected Lack of Efficacy of Liposomal-Encapsulated Daunorubicin/Cytarabine in Pediatric <i>FLT3</i> Wild-Type Newly Diagnosed AMLhttps://www.pharmaradar360.com/article/reply-to-pcwg4-a-missed-opportunity-to-make-bone-protective-agents-mandatory-for-7a9a4131b9d688d0PharmaRadar360en2026-09-20T00:00:00.000ZReply to: PCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancerhttps://www.pharmaradar360.com/article/reply-to-beyond-response-rates-interpreting-long-term-benefit-in-checkmate-743-a-680b2d81daece5b2PharmaRadar360en2026-09-20T00:00:00.000ZReply to: “Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743” and “Beyond Statistical Significance: Methodologic Fragility and Censoring Bias in the 5-Year Update of CheckMate 743”https://www.pharmaradar360.com/article/beyond-statistical-significance-methodologic-fragility-and-censoring-bias-in-the-5888645062177c61PharmaRadar360en2026-09-20T00:00:00.000ZBeyond Statistical Significance: Methodologic Fragility and Censoring Bias in the 5-Year Update of CheckMate 743https://www.pharmaradar360.com/article/rituximab-maintenance-added-to-ibrutinib-containing-therapy-in-younger-untreated-f591e24ba0a91e9bPharmaRadar360en2026-09-20T00:00:00.000ZRituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trialhttps://www.pharmaradar360.com/article/biomarker-stratified-phase-ii-trial-of-trastuzumab-rezetecan-in-advanced-salivar-e9a9c59fc3d6e970PharmaRadar360en2026-09-20T00:00:00.000ZBiomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expressionhttps://www.pharmaradar360.com/article/pcwg4-a-missed-opportunity-to-make-bone-protective-agents-mandatory-for-patients-ad9901af9cd08618PharmaRadar360en2026-09-20T00:00:00.000ZPCWG4: A Missed Opportunity to Make Bone-Protective Agents Mandatory for Patients With Bone Metastatic Castration-Resistant Prostate Cancerhttps://www.pharmaradar360.com/article/balancing-risk-benefit-and-reality-navigating-early-phase-studies-in-pediatric-d-b48bafd2e92e4718PharmaRadar360en2026-09-20T00:00:00.000ZBalancing Risk, Benefit, and Reality: Navigating Early Phase Studies in Pediatric Diffuse Midline Gliomahttps://www.pharmaradar360.com/article/darolutamide-alone-and-in-combination-with-goserelin-in-androgen-receptor-positi-392f7023f6ac4646PharmaRadar360en2026-09-20T00:00:00.000ZDarolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trialhttps://www.pharmaradar360.com/article/mosunetuzumab-with-response-adapted-polatuzumab-vedotin-and-obinutuzumab-in-untr-e44840b20d6dfe8cPharmaRadar360en2026-09-20T00:00:00.000ZMosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphomahttps://www.pharmaradar360.com/article/laser-interstitial-thermal-therapy-for-brain-tumors-a-prospective-multicenter-an-09e60a65ac19d6f3PharmaRadar360en2026-09-20T00:00:00.000ZLaser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Studyhttps://www.pharmaradar360.com/article/long-term-follow-up-of-jcog1008-a-randomized-phase-ii-iii-trial-of-chemoradiothe-b4cc18dcf9a39115PharmaRadar360en2026-09-20T00:00:00.000ZLong-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancerhttps://www.pharmaradar360.com/article/assessing-improved-surveillance-of-leprosy-drug-resistance-in-madagascar-a-pilot-8c4a97f423db1efePharmaRadar360en2026-09-20T00:00:00.000ZAssessing improved surveillance of leprosy drug resistance in Madagascar: a pilot study in the Miandrivazo districthttps://www.pharmaradar360.com/article/clinical-outcomes-and-factors-associated-with-lower-pole-ptosis-recurrence-after-83dea2b3c8709bc6PharmaRadar360en2026-09-20T00:00:00.000ZClinical outcomes and factors associated with lower-pole ptosis recurrence after superomedial pedicle breast reduction with glandular flap suspension: a retrospective studyhttps://www.pharmaradar360.com/article/scalable-clinical-proteomics-from-dna-rna-extraction-flowthroughs-enables-integr-67f4d99a37666c5ePharmaRadar360en2026-09-20T00:00:00.000ZScalable clinical proteomics from DNA/RNA extraction flowthroughs enables integrated proteogenomic profiling from a single cancer biopsyhttps://www.pharmaradar360.com/article/drug-drug-interaction-between-alpinetin-and-glimepiride-and-its-potential-mechan-3fe3d3d640e3aac3PharmaRadar360en2026-09-20T00:00:00.000ZDrug-drug Interaction Between Alpinetin and Glimepiride and its Potential Mechanism in Ratshttps://www.pharmaradar360.com/article/individualized-breast-cancer-survival-prediction-in-clinical-practice-a-seer-der-3515bc4647f92f29PharmaRadar360en2026-09-20T00:00:00.000ZIndividualized breast cancer survival prediction in clinical practice: a SEER-derived interactive web tool integrating molecular and anatomical factorshttps://www.pharmaradar360.com/article/vestibular-rehabilitation-therapy-in-turkey-insights-into-physical-therapists-cl-e15ab512d701d115PharmaRadar360en2026-09-20T00:00:00.000ZVestibular rehabilitation therapy in Turkey: insights into physical therapists’ clinical practicehttps://www.pharmaradar360.com/article/delayed-antiretroviral-refills-as-an-early-clinical-alert-a-pharmacist-led-strat-5ed4eb24ac199b96PharmaRadar360en2026-09-20T00:00:00.000ZDelayed antiretroviral refills as an early clinical alert: a pharmacist-led strategy to improve viral suppression in Malaysiahttps://www.pharmaradar360.com/article/development-and-external-validation-of-prediction-models-for-a-trial-informed-op-734bcdaeee93453aPharmaRadar360en2026-09-20T00:00:00.000ZDevelopment and external validation of prediction models for a trial-informed operational composite after stage 3 acute kidney injuryhttps://www.pharmaradar360.com/article/bedside-infrared-thermometry-compared-with-continuous-zero-heat-flux-thermometry-3288242dafa136cePharmaRadar360en2026-09-20T00:00:00.000ZBedside infrared thermometry compared with continuous zero-heat-flux thermometry– an experimental and clinical studyhttps://www.pharmaradar360.com/article/the-marine-drug-plitidepsin-alleviates-osteoporosis-in-estrogen-deficient-mice-b-515952451def30c3PharmaRadar360en2026-09-20T00:00:00.000ZThe marine drug plitidepsin alleviates osteoporosis in estrogen-deficient mice by suppressing ROS-mediated NRF2/HO-1 signaling and osteoclast formationhttps://www.pharmaradar360.com/article/integrated-sustainability-and-risk-assessment-of-spectrophotometric-methods-for-37c16b3a77f6077ePharmaRadar360en2026-09-20T00:00:00.000ZIntegrated sustainability and risk assessment of spectrophotometric methods for determining a veterinary drug combinationhttps://www.pharmaradar360.com/article/multicenter-dataset-describing-emotional-intelligence-and-counseling-self-effica-6689624137da0a45PharmaRadar360en2026-09-20T00:00:00.000ZMulticenter dataset describing emotional intelligence and counseling self-efficacy among clinical pastoral education students in healthcare settingshttps://www.pharmaradar360.com/article/association-between-serum-cotinine-levels-and-prostate-related-clinical-endpoint-c4f852f4c83f757bPharmaRadar360en2026-09-20T00:00:00.000ZAssociation between serum cotinine levels and prostate-related clinical endpointshttps://www.pharmaradar360.com/article/understanding-the-impact-of-multiple-long-term-conditions-mltc-on-the-completion-e5c5b1b4afada493PharmaRadar360en2026-09-20T00:00:00.000ZUnderstanding the impact of Multiple Long-Term Conditions (MLTC) on the completion of delirium screening documentation: analysis using routinely collected clinical datahttps://www.pharmaradar360.com/article/interest-in-geriatric-medicine-training-among-health-and-social-care-professiona-9f3f04d231090ca3PharmaRadar360en2026-09-20T00:00:00.000ZInterest in geriatric medicine training among health and social care professionals: the roles of experience and attitudes. Findings from the online survey of the COST Action PROGRAMMING 21122https://www.pharmaradar360.com/article/the-who-isop-pharmacovigilance-curriculum-2026-update-caba9d183fe05317PharmaRadar360en2026-09-20T00:00:00.000ZThe WHO-ISoP Pharmacovigilance Curriculum: 2026 Updatehttps://www.pharmaradar360.com/article/upstream-regulatory-mechanisms-and-clinical-significance-of-iqgap2-deficiency-in-606950dc4cbfd91dPharmaRadar360en2026-09-20T00:00:00.000ZUpstream regulatory mechanisms and clinical significance of IQGAP2 deficiency in affecting PI3K activity to drive cell proliferationhttps://www.pharmaradar360.com/article/identification-of-sst-as-a-glioblastoma-diagnostic-biomarker-via-integrated-bulk-68922ea308c6ef9bPharmaRadar360en2026-09-20T00:00:00.000ZIdentification of SST as a glioblastoma diagnostic biomarker via integrated bulk and single-cell transcriptomics and DrugReflector AI-driven drug discoveryhttps://www.pharmaradar360.com/article/slfn5-correlates-with-tumor-immune-microenvironment-and-clinical-outcomes-of-imm-9ab3dc157165f755PharmaRadar360en2026-09-20T00:00:00.000ZSLFN5 correlates with tumor immune microenvironment and clinical outcomes of immunotherapy in melanomahttps://www.pharmaradar360.com/article/confounding-by-indication-in-the-evaluation-of-neoadjuvant-chemotherapy-a-sequen-a053b317c6b33cacPharmaRadar360en2026-09-20T00:00:00.000ZConfounding by indication in the evaluation of neoadjuvant chemotherapy: a sequential Cox analysis of an eight-year single-centre breast cancer cohorthttps://www.pharmaradar360.com/article/bridging-the-data-latency-gap-automated-extraction-of-genomic-biomarkers-from-un-5a6e7536de41241bPharmaRadar360en2026-09-20T00:00:00.000ZBridging the data latency gap: automated extraction of genomic biomarkers from unstructured clinical documents to support real-world oncology datahttps://www.pharmaradar360.com/article/randomized-trial-comparing-esophageal-resection-versus-substitution-alone-for-co-2c1a150a1149681dPharmaRadar360en2026-09-20T00:00:00.000ZRandomized trial comparing esophageal resection versus substitution alone for corrosive esophageal strictureshttps://www.pharmaradar360.com/article/association-of-genetic-polymorphisms-with-response-to-preoperative-nsaids-in-end-27f802965350b2c4PharmaRadar360en2026-09-20T00:00:00.000ZAssociation of genetic polymorphisms with response to preoperative NSAIDs in endodontic postoperative pain: a randomized double-blind placebo-controlled clinical trialhttps://www.pharmaradar360.com/article/metabolomics-of-immunosenescence-bridging-blood-biomarkers-and-metabolic-pathway-71710cedb23a4736PharmaRadar360en2026-09-20T00:00:00.000ZMetabolomics of immunosenescence: bridging blood biomarkers and metabolic pathways in aginghttps://www.pharmaradar360.com/article/persistent-foot-and-ankle-pain-in-rheumatoid-arthritis-remission-what-is-the-tre-ec95eeebc6741fa8PharmaRadar360en2026-09-20T00:00:00.000ZPersistent foot and ankle pain in rheumatoid arthritis remission: what is the treatment target?https://www.pharmaradar360.com/article/oncogene-driven-genomic-profiles-are-linked-to-poor-overall-survival-in-muscle-i-ad57ae7a9b681197PharmaRadar360en2026-09-20T00:00:00.000ZOncogene-driven genomic profiles are linked to poor overall survival in muscle-invasive bladder cancer (MIBC)https://www.pharmaradar360.com/article/visual-snow-syndrome-as-a-neuropsychiatric-network-disorder-clinical-features-me-8b7cb71781bfa6e8PharmaRadar360en2026-09-20T00:00:00.000ZVisual snow syndrome as a neuropsychiatric network disorder: clinical features, mechanisms, and therapeutic perspectiveshttps://www.pharmaradar360.com/article/evaluation-of-clinical-and-follow-up-data-in-patients-with-mycosis-fungoides-a-1-78724b981987fd8fPharmaRadar360en2026-09-20T00:00:00.000ZEvaluation of clinical and follow-up data in patients with mycosis fungoides: a 10-year single-centre experiencehttps://www.pharmaradar360.com/article/fear-of-isotretinoin-in-moderate-to-severe-acne-clinical-impact-and-a-new-assess-b676c6d7f12c9224PharmaRadar360en2026-09-20T00:00:00.000ZFear of isotretinoin in moderate-to-severe acne: clinical impact and a new assessment approachhttps://www.pharmaradar360.com/article/imaging-in-gynecological-disease-32-clinical-and-ultrasound-characteristics-of-e-d66a8d1c162ad3b3PharmaRadar360en2026-09-20T00:00:00.000ZImaging in gynecological disease (32): clinical and ultrasound characteristics of early abdominal ectopic pregnancyhttps://www.pharmaradar360.com/article/statins-as-repurposed-anticancer-agents-regulated-cell-death-the-tumor-immune-mi-876ff52221583627PharmaRadar360en2026-09-20T00:00:00.000ZStatins as Repurposed Anticancer Agents: Regulated Cell Death, the Tumor Immune Microenvironment, and the Translational Evidence Gaphttps://www.pharmaradar360.com/article/muireann-counihan-the-school-of-pharmacy-and-pharmaceutical-sciences-c41c155632d597a0PharmaRadar360en2026-09-19T23:15:28.000ZMuireann Counihan - The School of Pharmacy and Pharmaceutical Scienceshttps://www.pharmaradar360.com/article/krx-healthcare-shifts-to-large-caps-as-korea-favors-new-tech-biomed-chosunbiz-b426b824b83acf3dPharmaRadar360en2026-09-19T23:00:00.000ZKRX Healthcare shifts to large caps as Korea favors new-tech biomed - CHOSUNBIZhttps://www.pharmaradar360.com/article/the-voice-the-school-of-pharmacy-and-pharmaceutical-sciences-241a1a36f55a527cPharmaRadar360en2026-09-19T22:50:28.000ZThe Voice - The School of Pharmacy and Pharmaceutical Scienceshttps://www.pharmaradar360.com/article/fda-advisers-narrowly-vote-to-add-6-peptides-to-a-drug-compounding-list-what-s-n-05eb0af1ede61b6fPharmaRadar360en2026-09-19T21:53:44.000ZFDA advisers narrowly vote to add 6 peptides to a drug compounding list. What's next?https://www.pharmaradar360.com/article/total-common-shares-outstanding-of-indrayani-biotech-ltd-right-2026-25-06-26-for-d681acd0241805f0PharmaRadar360en2026-09-19T21:04:42.000ZTotal common shares outstanding of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/return-on-assets-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-ind-501f187a0924faecPharmaRadar360en2026-09-19T21:04:42.000ZReturn on assets % of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/net-current-asset-value-per-share-of-indrayani-biotech-ltd-right-2026-25-06-26-f-e6b6622493611352PharmaRadar360en2026-09-19T21:03:58.000ZNet current asset value per share of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/total-debt-per-share-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-16236a055fbe9757PharmaRadar360en2026-09-19T21:02:22.000ZTotal debt per share of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/quick-ratio-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-6581b40f0bba1e8dPharmaRadar360en2026-09-19T21:02:07.000ZQuick ratio of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/messenger-rna-based-flu-vaccine-makes-its-debut-in-u-s-pharmacies-who-can-get-it-efefc51acff05862PharmaRadar360en2026-09-19T21:01:27.000ZMessenger RNA-Based Flu Vaccine Makes Its Debut in U.S. Pharmacies: Who Can Get It?https://www.pharmaradar360.com/article/inventory-turnover-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-i-5671ae1604807dc6PharmaRadar360en2026-09-19T20:59:43.000ZInventory turnover of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/enterprise-value-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-ind-4dff78ae4aa050dbPharmaRadar360en2026-09-19T20:59:12.000ZEnterprise value of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/capex-per-share-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indr-944f01d354552ab8PharmaRadar360en2026-09-19T20:56:40.000ZCapEx per share of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/debt-to-equity-ratio-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-310711ff40bee6ddPharmaRadar360en2026-09-19T20:56:07.000ZDebt to equity ratio of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/price-to-cash-flow-ratio-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-9af57061cd64e28aPharmaRadar360en2026-09-19T20:55:52.000ZPrice to cash flow ratio of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/book-value-per-share-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-fc227e4d6c502179PharmaRadar360en2026-09-19T20:55:49.000ZBook value per share of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/debt-to-assets-ratio-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-ad7a8697f95d971cPharmaRadar360en2026-09-19T20:55:39.000ZDebt to assets ratio of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-indrayani-biotech-ltd-right-2026-25-06-26-fo-7d4300fa5e85e482PharmaRadar360en2026-09-19T20:55:36.000ZEnterprise value to EBIT forward of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/operating-margin-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-ind-a7fd04be177b342ePharmaRadar360en2026-09-19T20:54:29.000ZOperating margin % of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/net-margin-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-44ae08b901252b4ePharmaRadar360en2026-09-19T20:54:06.000ZNet margin % of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/ai-biotech-without-humans-stanford-deploys-37-000-agents-to-hunt-new-therapies-d11375b86fdfc5b8PharmaRadar360en2026-09-19T20:30:04.000ZAI biotech without humans? Stanford deploys 37,000 agents to hunt new therapieshttps://www.pharmaradar360.com/article/abbvie-s-migraine-franchise-scored-a-big-win-is-this-dividend-king-a-no-brainer-76f1564f042c6f89PharmaRadar360en2026-09-19T19:48:17.000ZAbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?https://www.pharmaradar360.com/article/indrayani-biotech-ltd-right-2026-25-06-26-for-shares-revenue-breakdown-bse-indra-ba030f2dd73a0499PharmaRadar360en2026-09-19T18:45:01.000ZIndrayani Biotech Ltd. Right 2026-25.06.26 For Shares Revenue Breakdown – BSE:INDRA_REhttps://www.pharmaradar360.com/article/operating-expenses-excl-cogs-of-indrayani-biotech-ltd-right-2026-25-06-26-for-sh-2736dd784b3621dfPharmaRadar360en2026-09-19T18:22:17.000ZOperating expenses (excl. COGS) of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/aap-ki-nazro-se-kuch-bachta-nahi-mallika-sherawat-thanks-fda-chief-tukaram-mundh-74720aa7f91d7267PharmaRadar360en2026-09-19T17:56:00.000Z'Aap ki nazro se kuch bachta nahi': Mallika Sherawat thanks FDA chief Tukaram Mundhe for food safety crachttps://www.pharmaradar360.com/article/book-value-per-share-of-teva-pharmaceutical-industries-limited-ls-906517-b020b70e7daa0d95PharmaRadar360en2026-09-19T17:02:39.000ZBook value per share of Teva Pharmaceutical Industries Limited – LS:906517https://www.pharmaradar360.com/article/secret-contracts-reveal-undisclosed-terms-in-trump-s-drug-pricing-deals-bcbb413fb30f9d63PharmaRadar360en2026-09-19T17:00:01.000ZSecret contracts reveal undisclosed terms in Trump’s drug-pricing dealshttps://www.pharmaradar360.com/article/cost-of-goods-sold-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-i-b0630789d0593e12PharmaRadar360en2026-09-19T16:51:55.000ZCost of goods sold of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/pretax-income-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-25138c424a649553PharmaRadar360en2026-09-19T16:30:23.000ZPretax income of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/total-revenue-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-e381ce93b7e938a6PharmaRadar360en2026-09-19T16:29:49.000ZTotal revenue of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/total-operating-expenses-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-91c124a406c23076PharmaRadar360en2026-09-19T16:29:45.000ZTotal operating expenses of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/cash-flow-from-operating-activities-of-indrayani-biotech-ltd-right-2026-25-06-26-231dd929df858043PharmaRadar360en2026-09-19T16:28:58.000ZCash flow from operating activities of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/how-direct-to-patient-is-redefining-drug-pricing-f6ef53a75af94d90PharmaRadar360en2026-09-19T16:27:03.000ZHow Direct-to-Patient Is Redefining Drug Pricinghttps://www.pharmaradar360.com/article/cash-flow-from-financing-activities-of-indrayani-biotech-ltd-right-2026-25-06-26-5f765c6bb4d289bePharmaRadar360en2026-09-19T16:26:55.000ZCash flow from financing activities of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/cash-flow-from-investing-activities-of-indrayani-biotech-ltd-right-2026-25-06-26-f5e9efda9ca345a9PharmaRadar360en2026-09-19T16:25:04.000ZCash flow from investing activities of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/average-basic-shares-outstanding-of-indrayani-biotech-ltd-right-2026-25-06-26-fo-ff947f5470cc2ca9PharmaRadar360en2026-09-19T16:24:59.000ZAverage basic shares outstanding of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/free-cash-flow-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-a3b2458b02b59529PharmaRadar360en2026-09-19T16:19:35.000ZFree cash flow of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/biotech-stocks-to-consider-september-19th-5211e452c4824f48PharmaRadar360en2026-09-19T16:04:26.000ZBiotech Stocks To Consider - September 19thhttps://www.pharmaradar360.com/article/a-melanoma-vaccine-was-hailed-as-a-breakthrough-which-cancers-are-next-9724080badd419c9PharmaRadar360en2026-09-19T16:00:00.000ZA melanoma vaccine was hailed as a breakthrough. Which cancers are next?https://www.pharmaradar360.com/article/operating-income-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-ind-22b6730b871044c2PharmaRadar360en2026-09-19T15:33:09.000ZOperating income of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/discontinued-operations-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-739c09f0cac42098PharmaRadar360en2026-09-19T15:32:30.000ZDiscontinued operations of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/net-income-before-discontinued-operations-of-indrayani-biotech-ltd-right-2026-25-29c58a19d8e3561cPharmaRadar360en2026-09-19T15:32:14.000ZNet income before discontinued operations of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/non-operating-income-total-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shar-f8f77254f0db8c18PharmaRadar360en2026-09-19T15:31:57.000ZNon-operating income (total) of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/ebit-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-3d34754992cd42f7PharmaRadar360en2026-09-19T15:31:46.000ZEBIT of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/west-pharmaceutical-stock-holds-moderate-buy-rating-as-annex-1-work-shapes-outlo-3c0fd62fb4220ec9PharmaRadar360en2026-09-19T15:29:24.000ZWest Pharmaceutical stock holds Moderate Buy rating as Annex 1 work shapes outlookhttps://www.pharmaradar360.com/article/preferred-dividends-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-7b282f168c26acd9PharmaRadar360en2026-09-19T15:28:58.000ZPreferred dividends of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/diluted-shares-outstanding-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shar-fe37fa0a86d75c4cPharmaRadar360en2026-09-19T15:28:18.000ZDiluted shares outstanding of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/indrayani-biotech-ltd-right-2026-25-06-26-for-shares-7015c7d5b069f15aPharmaRadar360en2026-09-19T15:25:54.000ZIndrayani Biotech Ltd. Right 2026-25.06.26 For Shareshttps://www.pharmaradar360.com/article/dilution-adjustment-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-2a92242613664e93PharmaRadar360en2026-09-19T15:24:31.000ZDilution adjustment of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/net-income-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-7bf5aee9b121472ePharmaRadar360en2026-09-19T15:23:53.000ZNet income of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/taxes-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-105d223587366115PharmaRadar360en2026-09-19T15:23:25.000ZTaxes of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/equity-in-earnings-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-i-6152711dc8c0ba7aPharmaRadar360en2026-09-19T15:23:03.000ZEquity in earnings of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/ebitda-of-indrayani-biotech-ltd-right-2026-25-06-26-for-shares-bse-indra-re-a4a85e2a8c739394PharmaRadar360en2026-09-19T15:22:51.000ZEBITDA of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/fda-approves-takeda-s-orzeyful-as-first-drug-to-treat-narcolepsy-type-1-cause-49d3fb93ffe19a13PharmaRadar360en2026-09-19T14:37:48.000ZFDA approves Takeda's ORZEYFUL as first drug to treat narcolepsy type 1 causehttps://www.pharmaradar360.com/article/oncolytics-biotech-stock-lacks-a-fresh-catalyst-and-stays-near-0-77-4ef9f2145181d3bbPharmaRadar360en2026-09-19T14:17:54.000ZOncolytics Biotech stock lacks a fresh catalyst and stays near $0.77https://www.pharmaradar360.com/article/what-is-drawing-fresh-attention-to-biomarin-pharmaceutical-bmrn-dd7670b3b7f47046PharmaRadar360en2026-09-19T14:12:22.000ZWhat Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?https://www.pharmaradar360.com/article/how-investors-are-reacting-to-ultragenyx-pharmaceutical-rare-first-in-disease-ge-39556364aa63f8c2PharmaRadar360en2026-09-19T14:10:33.000ZHow Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVIhttps://www.pharmaradar360.com/article/oveporexton-met-primary-key-secondary-end-points-in-phase-3-studies-f55b262789759abcPharmaRadar360en2026-09-19T14:10:03.000ZOveporexton Met Primary, Key Secondary End Points in Phase 3 Studieshttps://www.pharmaradar360.com/article/doctors-without-borders-launches-ebola-vaccination-study-in-dr-congo-bfd423e85dc532e3PharmaRadar360en2026-09-19T14:02:08.000ZDoctors Without Borders launches Ebola vaccination study in DR Congohttps://www.pharmaradar360.com/article/drug-transparency-bill-stripped-of-critical-provisions-ahead-of-senate-vote-b7b7e4539be30c15PharmaRadar360en2026-09-19T14:01:40.000ZDrug Transparency Bill Stripped of Critical Provisions Ahead of Senate Votehttps://www.pharmaradar360.com/article/mumbai-s-olympia-coffee-house-where-christopher-nolan-and-matt-damon-had-chai-fa-45ca75e3790f9d9dPharmaRadar360en2026-09-19T13:44:17.000ZMumbai's Olympia Coffee House, where Christopher Nolan and Matt Damon had chai, faces FDA licence suspensionhttps://www.pharmaradar360.com/article/egg-recall-linked-to-salmonella-upgraded-to-highest-risk-level-by-fda-151a459787e48b10PharmaRadar360en2026-09-19T13:40:56.000ZEgg recall linked to salmonella upgraded to highest risk level by FDAhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-stock-edges-lower-as-analysts-keep-moderate-buy-stance-474386a21dda61b3PharmaRadar360en2026-09-19T13:33:57.000ZCollegium Pharmaceutical stock edges lower as analysts keep Moderate Buy stancehttps://www.pharmaradar360.com/article/where-nolan-tom-holland-had-chai-mumbai-cafe-faces-fda-licence-suspension-653993cb5cb20817PharmaRadar360en2026-09-19T13:04:58.000ZWhere Nolan, Tom Holland had chai: Mumbai cafe faces FDA licence suspensionhttps://www.pharmaradar360.com/article/passaparola-21-09-120-anni-della-clinica-mangiagalli-celebriamo-la-culla-d-itali-b6f1cc699352db07PharmaRadar360en2026-09-19T13:00:00.000Z#PASSAPAROLA [21.09] 120 anni della Clinica Mangiagalli: celebriamo la culla d’Italiahttps://www.pharmaradar360.com/article/opthea-limited-stock-steadies-as-phase-3-trial-progress-drives-investor-focus-7dd5c0af77aa118aPharmaRadar360en2026-09-19T12:29:41.000ZOpthea Limited stock steadies as phase 3 trial progress drives investor focushttps://www.pharmaradar360.com/article/more-than-3-million-bottles-of-eye-drops-sold-at-cvs-kroger-more-voluntarily-rec-841b0d51339f6beePharmaRadar360en2026-09-19T12:26:18.000ZMore than 3 million bottles of eye drops sold at CVS, Kroger, more voluntarily recalledhttps://www.pharmaradar360.com/article/mallika-sherawat-praises-maharashtra-fda-commissioner-tukaram-mundhe-amid-state-3d5cc3b648250527PharmaRadar360en2026-09-19T12:15:31.000ZMallika Sherawat Praises Maharashtra FDA Commissioner Tukaram Mundhe Amid State-Wide Food Safety Crackdownhttps://www.pharmaradar360.com/article/macrogenics-stock-edges-lower-as-biotech-analysts-highlight-risk-and-upside-e9cf4e74587d279dPharmaRadar360en2026-09-19T12:15:12.000ZMacroGenics stock edges lower as biotech analysts highlight risk and upsidehttps://www.pharmaradar360.com/article/this-tiny-biotech-is-beating-mrna-iova-and-sls-here-s-how-a-billionaire-fueled-i-f9fadbaa2502bed3PharmaRadar360en2026-09-19T12:01:44.000ZThis Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rallyhttps://www.pharmaradar360.com/article/rassegnastampa-tumori-in-eta-pediatrica-favorire-le-prospettive-di-guarigione-ne-533dc6a088ec60cePharmaRadar360en2026-09-19T11:58:00.000Z#RASSEGNASTAMPA. Tumori in età pediatrica: favorire le prospettive di guarigione. Ne parla Ernesto Leva a TG4 Medicinahttps://www.pharmaradar360.com/article/latus-bio-adds-biotech-veterans-as-gene-therapies-enter-clinic-d758e89343372953PharmaRadar360en2026-09-19T11:37:30.000ZLatus Bio Adds Biotech Veterans as Gene Therapies Enter Clinichttps://www.pharmaradar360.com/article/chip-tech-to-biotech-ce2e02f56139299fPharmaRadar360en2026-09-19T11:30:00.000ZChip tech to biotechhttps://www.pharmaradar360.com/article/basic-earnings-per-share-basic-eps-of-indrayani-biotech-ltd-right-2026-25-06-26-6078a04cee3109b7PharmaRadar360en2026-09-19T11:26:00.000ZBasic earnings per share (basic EPS) of Indrayani Biotech Ltd. Right 2026-25.06.26 For Shares – BSE:INDRA_REhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-19T10:52:34.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-insider-trading-activity-2026-249623a1453a3bf2PharmaRadar360en2026-09-19T10:43:00.000ZVeraxa Biotech (VRXA) Insider Trading Activity 2026https://www.pharmaradar360.com/article/top-10-pharmaceutical-manufacturing-companies-in-africa-in-2026-b4a1093df370deb8PharmaRadar360en2026-09-19T10:42:10.000ZTop 10 Pharmaceutical Manufacturing Companies in Africa in 2026https://www.pharmaradar360.com/article/emirates-biotech-uae-university-partner-on-food-waste-plant-for-biogas-compost-5fbfd1099eb088dbPharmaRadar360en2026-09-19T10:33:23.000ZEmirates Biotech, UAE University partner on food waste plant for biogas, composthttps://www.pharmaradar360.com/article/dftx-vs-cmps-which-stock-has-more-upside-from-trump-s-new-psychedelic-therapy-pu-ef64dcf5e3960581PharmaRadar360en2026-09-19T10:24:50.000ZDFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?https://www.pharmaradar360.com/article/cassava-sciences-stock-holds-near-recent-lows-as-biotech-losses-and-mixed-sentim-d4ec6f7ef586a00bPharmaRadar360en2026-09-19T10:10:12.000ZCassava Sciences stock holds near recent lows as biotech losses and mixed sentiment weighhttps://www.pharmaradar360.com/article/fda-examines-use-of-testosterone-prescriptions-for-menopause-ad0f106a02d24ff0PharmaRadar360en2026-09-19T10:05:03.000ZFDA examines use of testosterone prescriptions for menopausehttps://www.pharmaradar360.com/article/tirupati-group-appoints-uday-k-potdar-as-chief-financial-officer-339f006e241d5b8dPharmaRadar360en2026-09-19T10:01:43.000ZTirupati Group Appoints Uday K. Potdar As Chief Financial Officerhttps://www.pharmaradar360.com/article/karnataka-approves-marine-biotech-policy-targets-6-8-bn-blue-bioeconomy-by-2031-2fb7e60f353058d0PharmaRadar360en2026-09-19T10:00:20.000ZKarnataka approves marine biotech policy, targets $6-8 bn blue bioeconomy by 2031https://www.pharmaradar360.com/article/another-novartis-failure-novo-drops-the-nordisk-and-more-12d3d548f946c7a8PharmaRadar360en2026-09-19T10:00:00.000ZAnother Novartis failure; Novo drops the ‘Nordisk’; and morehttps://www.pharmaradar360.com/article/vaccinex-stock-holds-at-1-00-dollars-as-investors-await-fresh-trial-and-earnings-e39c8770527cfb72PharmaRadar360en2026-09-19T09:32:43.000ZVaccinex stock holds at 1.00 dollars as investors await fresh trial and earnings updateshttps://www.pharmaradar360.com/article/ordinary-people-pay-price-iran-medicine-shortages-deepen-as-war-continues-25bdcfd142278adePharmaRadar360en2026-09-19T09:30:32.000Z‘Ordinary people pay price’: Iran medicine shortages deepen as war continueshttps://www.pharmaradar360.com/article/tukaram-mundhe-joke-to-amitabh-rekha-reference-samay-raina-s-latest-latent-episo-32630065385d1595PharmaRadar360en2026-09-19T09:27:16.000ZTukaram Mundhe joke to Amitabh-Rekha reference: Samay Raina’s latest Latent episode goes viralhttps://www.pharmaradar360.com/article/takeda-wins-fda-approval-for-mimrylo-triggers-275m-payout-to-protagonist-819356fbe3d593e7PharmaRadar360en2026-09-19T09:16:45.000ZTakeda wins FDA approval for MIMRYLO, triggers $275m payout to Protagonisthttps://www.pharmaradar360.com/article/weekend-longforms-organ-donation-false-pregnancy-tests-cancer-drug-ai-for-diagno-94dc4d3b8d04d5d9PharmaRadar360en2026-09-19T09:09:54.000ZWeekend Longforms: organ donation, false pregnancy tests, cancer drug, AI for diagnosis, and denial appeals. Animal photo, toohttps://www.pharmaradar360.com/article/medicine-shortages-deepen-in-iran-amid-war-shipping-restrictions-1722387ef29ee867PharmaRadar360en2026-09-19T08:18:00.000ZMedicine shortages deepen in Iran amid war, shipping restrictionshttps://www.pharmaradar360.com/article/ganpati-meets-food-safety-navi-mumbai-pandal-honours-tukaram-mundhes-fda-work-wi-8edca60af6c53510PharmaRadar360en2026-09-19T07:37:17.000ZGanpati Meets Food Safety! Navi Mumbai Pandal Honours Tukaram Mundhes FDA Work With Unique Ganesh Decor Themehttps://www.pharmaradar360.com/article/equity-in-earnings-of-zhuhai-trinomab-pharmaceutical-co-ltd-class-a-sse-688806-e04ee5f175d57b5aPharmaRadar360en2026-09-19T07:27:52.000ZEquity in earnings of Zhuhai Trinomab Pharmaceutical Co., Ltd. Class A – SSE:688806https://www.pharmaradar360.com/article/price-to-book-forward-of-henan-taloph-pharmaceutical-stock-co-ltd-class-a-sse-60-2bc42da5d2afe758PharmaRadar360en2026-09-19T07:27:29.000ZPrice to book forward of Henan Taloph Pharmaceutical Stock Co. Ltd. Class A – SSE:600222https://www.pharmaradar360.com/article/teva-s-tev-749-olanzapine-lai-shows-80-stabilization-rate-in-schizophrenia-trial-90a9d7a77742a0d4PharmaRadar360en2026-09-19T06:42:48.000ZTeva’s TEV-749 olanzapine LAI shows 80% stabilization rate in schizophrenia trialhttps://www.pharmaradar360.com/article/fda-approves-imlunestrant-plus-abemaciclib-for-esr1-mutated-breast-cancer-3c625593f647ec48PharmaRadar360en2026-09-19T06:37:48.000ZFDA approves imlunestrant plus abemaciclib for ESR1-mutated breast cancerhttps://www.pharmaradar360.com/article/alumna-employs-biotech-to-create-sustainable-livestock-production-f241526028de166dPharmaRadar360en2026-09-19T06:00:00.000ZAlumna employs biotech to create sustainable livestock productionhttps://www.pharmaradar360.com/article/remember-when-christopher-nolan-and-tom-holland-visited-now-this-legendary-colab-a24659359e79565bPharmaRadar360en2026-09-19T05:28:21.000ZRemember when Christopher Nolan and Tom Holland visited? Now this legendary Colaba Cafe faces suspensionhttps://www.pharmaradar360.com/article/neuphoria-to-be-acquired-by-scancell-in-all-stock-merger-b15a4e3511e1bdbfPharmaRadar360en2026-09-19T05:23:00.000ZNeuphoria to Be Acquired by Scancell in All-Stock Mergerhttps://www.pharmaradar360.com/article/iraq-customs-clarifies-duties-on-pharmaceuticals-vitamins-and-supplements-8cc25463c2e436b0PharmaRadar360en2026-09-19T05:13:48.000ZIraq Customs clarifies duties on pharmaceuticals, vitamins, and supplementshttps://www.pharmaradar360.com/article/pharmtech-weekly-roundup-september-18-2026-177f47cf9e1b228bPharmaRadar360en2026-09-19T05:07:01.000ZPharmTech Weekly Roundup—September 18, 2026https://www.pharmaradar360.com/article/welcome-to-the-mammosphere-f5899a492f6d03cdPharmaRadar360en2026-09-19T02:45:14.000ZWelcome to the mammospherehttps://www.pharmaradar360.com/article/how-annex-1-upgrades-at-west-pharmaceutical-services-wst-have-changed-its-invest-c6d42c01254a7c15PharmaRadar360en2026-09-19T02:42:21.000ZHow Annex 1 Upgrades At West Pharmaceutical Services (WST) Have Changed Its Investment Storyhttps://www.pharmaradar360.com/article/mumbai-latest-news-today-on-september-19th-2026-train-blocks-fda-action-universi-425568d9eca4bec5PharmaRadar360en2026-09-19T02:41:17.000ZMumbai Latest News Today on September 19th, 2026: Train Blocks, FDA Action & University Inaugurationhttps://www.pharmaradar360.com/article/astrazeneca-halts-one-lung-cancer-trial-after-mixed-phase-3-results-aba6e0c9f3b21761PharmaRadar360en2026-09-19T02:26:43.000ZAstraZeneca halts one lung cancer trial after mixed Phase 3 resultshttps://www.pharmaradar360.com/article/fda-hearing-psychedelics-launch-needs-balanced-regulation-without-limiting-acces-81cc63fd87c8c2d5PharmaRadar360en2026-09-19T02:15:00.000ZFDA hearing: psychedelics launch needs balanced regulation without limiting accesshttps://www.pharmaradar360.com/article/astrazeneca-amgen-tezspire-meets-phase-iii-eoe-trial-endpoints-f0706148fc31c54cPharmaRadar360en2026-09-19T01:34:06.000ZAstraZeneca, Amgen TEZSPIRE meets Phase III EoE trial endpointshttps://www.pharmaradar360.com/article/homilia-te-deum-una-casa-edificada-sobre-roca-470e28c9f1d5d8c9PharmaRadar360en2026-09-19T00:08:42.000ZHomilía Te Deum: Una casa edificada sobre rocahttps://www.pharmaradar360.com/article/transarterial-infusion-chemotherapy-and-embolization-as-a-novel-neoadjuvant-ther-7aac60eaf852135bPharmaRadar360en2026-09-19T00:00:00.000ZTransarterial infusion chemotherapy and embolization as a novel neoadjuvant therapy for locally advanced gastric cancer: a prospective single-arm pilot studyhttps://www.pharmaradar360.com/article/neo-bcv-induces-macrophage-associated-immunometabolic-remodeling-and-anti-tumor-0c165255b6a8071fPharmaRadar360en2026-09-19T00:00:00.000ZNeo-BCV induces macrophage-associated immunometabolic remodeling and anti-tumor immunity in solid tumorshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-suhuang-zhike-capsule-for-post-infectious-cough-a-multice-36ac1b41d34dc91ePharmaRadar360en2026-09-19T00:00:00.000ZEfficacy and Safety of Suhuang Zhike Capsule for Post-infectious Cough: A Multicenter, Single-arm, Open-label Phase IV Study.https://www.pharmaradar360.com/article/the-impact-of-antihypertensive-de-escalation-a-secondary-analysis-of-systolic-bl-8788c16a1547f799PharmaRadar360en2026-09-19T00:00:00.000ZThe Impact of Antihypertensive De-escalation: A Secondary Analysis of Systolic Blood Pressure Intervention Trial (SPRINT).https://www.pharmaradar360.com/article/safe-medicine-storage-and-disposal-among-pharmacy-and-engineering-students-a-kap-e3e2d4de32f25ed1PharmaRadar360en2026-09-19T00:00:00.000ZSafe Medicine Storage and Disposal among Pharmacy and Engineering Students: A Kap Study with Pre-Post Knowledge Assessmenthttps://www.pharmaradar360.com/article/mpox-outbreak-in-cote-d-ivoire-during-2024-epidemiological-clinical-virological-2027dc5ac6527c47PharmaRadar360en2026-09-19T00:00:00.000ZMpox Outbreak in Côte d'Ivoire during 2024: Epidemiological, Clinical, Virological and Outcome Features of Hospitalised Cases in Abidjanhttps://www.pharmaradar360.com/article/regenerative-medicine-in-the-management-of-musculoskeletal-pain-mechanisms-clini-d650a4d034f3b544PharmaRadar360en2026-09-19T00:00:00.000ZRegenerative Medicine in the Management of Musculoskeletal Pain: Mechanisms, Clinical Applications, and Future Directionshttps://www.pharmaradar360.com/article/clinical-efficacy-of-minimally-invasive-technologies-in-the-treatment-of-obstruc-b2e082ddcb04ca29PharmaRadar360en2026-09-19T00:00:00.000ZCLINICAL EFFICACY OF MINIMALLY INVASIVE TECHNOLOGIES IN THE TREATMENT OF OBSTRUCTIVE JAUNDICE ASSOCIATED WITH CHOLEDOCHOLITHIASIShttps://www.pharmaradar360.com/article/the-role-of-physicians-in-child-and-adolescent-psychiatry-exploring-the-therapeu-95303ae91b93ede6PharmaRadar360en2026-09-19T00:00:00.000ZThe Role of Physicians in Child and Adolescent Psychiatry: Exploring the Therapeutic Potential of Herbal Remedieshttps://www.pharmaradar360.com/article/examination-of-international-strategies-and-collaborative-efforts-in-responding-dcbf1a1c7f477fb6PharmaRadar360en2026-09-19T00:00:00.000ZExamination of International Strategies and Collaborative Efforts in Responding to the Ebola Crisis in West Africa: Lessons from the 2026 Bundibugyo Outbreak in the Democratic Republic of the Congo and Ugandahttps://www.pharmaradar360.com/article/efficacy-of-gs-441524-in-the-management-of-feline-infectious-peritonitis-a-clini-2b94abafbc0802b3PharmaRadar360en2026-09-19T00:00:00.000ZEfficacy of GS-441524 in the Management of Feline Infectious Peritonitis: A Clinical Studyhttps://www.pharmaradar360.com/article/serum-nfl-and-gfap-levels-and-their-association-with-anxiety-depression-in-alzhe-38114244d078d939PharmaRadar360en2026-09-19T00:00:00.000ZSerum NfL and GFAP levels and their association with anxiety-depression in Alzheimer’s disease patients: A clinical retrospective studyhttps://www.pharmaradar360.com/article/takotsubo-syndrome-a-review-of-psychobiological-mechanisms-and-clinical-practice-796f14de12226badPharmaRadar360en2026-09-19T00:00:00.000ZTakotsubo syndrome: A review of psychobiological mechanisms and clinical practice interventionshttps://www.pharmaradar360.com/article/from-correlation-to-intervention-translating-the-psychological-network-of-adoles-b02a37b1b055f61ePharmaRadar360en2026-09-19T00:00:00.000ZFrom correlation to intervention: Translating the psychological network of adolescent non-suicidal self-injury into clinical practicehttps://www.pharmaradar360.com/article/lt-b-gt-thiet-lap-ca-hai-tham-so-cua-bieu-o-kiem-soat-noi-kiem-hanh-lang-can-tre-a089bde4f7254a16PharmaRadar360en2026-09-19T00:00:00.000Z&lt;b&gt;THIẾT LẬP CẢ HAI THAM SỐ CỦA BIỂU ĐỒ KIỂM SOÁT NỘI KIỂM: HÀNH LANG CẬN TRÊN-CẬN DƯỚI CỦA ĐỘ KHÔNG CHỤM CHO GIỚI HẠN VÀ ĐỐI CHIẾU NGOẠI KIỂM CHO TRUNG BÌNH - NGHIÊN CỨU TRÊN 24 XÉT NGHIỆM HOÁ SINH&lt;/b&gt;https://www.pharmaradar360.com/article/lt-b-gt-khao-sat-chi-so-triglyceride-glucose-lt-b-gt-lt-b-gt-tyg-lt-b-gt-lt-b-gt-9aa3330e763554d0PharmaRadar360en2026-09-19T00:00:00.000Z&lt;b&gt;KHẢO SÁT CHỈ SỐ TRIGLYCERIDE-GLUCOSE&lt;/b&gt;&lt;b&gt; (TYG)&lt;/b&gt;&lt;b&gt; VÀ MỐI LIÊN QUAN VỚI MỘT SỐ &lt;/b&gt;&lt;b&gt;&lt;/b&gt; &lt;b&gt;ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG Ở BỆNH NHÂN GOUT &lt;/b&gt;&lt;b&gt;&lt;/b&gt;https://www.pharmaradar360.com/article/beyond-the-site-of-pain-fascial-continuity-and-integrated-clinical-reasoning-in-0df9516427501ea6PharmaRadar360en2026-09-19T00:00:00.000ZBEYOND THE SITE OF PAIN: FASCIAL CONTINUITY AND INTEGRATED CLINICAL REASONING IN MANUAL THERAPYhttps://www.pharmaradar360.com/article/proenkephalin-penkid-in-renal-dysfunction-an-integrative-review-of-laboratory-an-93660ff9cfd11b01PharmaRadar360en2026-09-19T00:00:00.000ZProenkephalin/penKid in renal dysfunction: An integrative review of laboratory and clinical evidencehttps://www.pharmaradar360.com/article/regenerative-medicine-at-the-crossroads-of-innovation-evidence-and-clinical-resp-05677a7f689b1c65PharmaRadar360en2026-09-19T00:00:00.000ZRegenerative medicine at the crossroads of innovation, evidence, and clinical responsibilityhttps://www.pharmaradar360.com/article/clinical-and-laboratory-profile-of-i-mycoplasma-pneumoniae-i-pneumonia-among-chi-552f7c94137766f9PharmaRadar360en2026-09-19T00:00:00.000ZClinical and Laboratory Profile of <i>Mycoplasma pneumoniae</i> Pneumonia among Children Aged 1 Month to 18 Years for 2 Years Admitted in a Tertiary Care Center: A Retrospective Studyhttps://www.pharmaradar360.com/article/inguinal-hernia-as-a-systemic-enzyme-dysfunction-disorder-a-prospective-comparat-e64f9953548400b0PharmaRadar360en2026-09-19T00:00:00.000ZInguinal Hernia as a Systemic Enzyme Dysfunction Disorder: A Prospective Comparative Study on the Role of Matrix Metalloproteinase-9 in The Transversalis Fasciahttps://www.pharmaradar360.com/article/the-psychological-impact-of-covid-19-and-mental-relaxation-practices-by-amateur-073b7c79da9ccae2PharmaRadar360en2026-09-19T00:00:00.000ZThe Psychological Impact of COVID -19 and Mental Relaxation Practices by Amateur Boxers: A Qualitative Studyhttps://www.pharmaradar360.com/article/ethnomedicinal-utilization-of-rauwolfia-serpentina-l-benth-ex-kurz-7d5ee8c80c1d7646PharmaRadar360en2026-09-19T00:00:00.000ZEthnomedicinal utilization of Rauwolfia serpentina (L.) Benth. ex Kurzhttps://www.pharmaradar360.com/article/computational-exploration-revealed-nicotiflorin-as-a-potent-dpp4-inhibitor-for-d-5a77b6dc254be1b5PharmaRadar360en2026-09-19T00:00:00.000ZComputational exploration revealed Nicotiflorin as a potent DPP4 inhibitor for diabetes management: Insights from network pharmacology, molecular docking, and molecular dynamics simulations studieshttps://www.pharmaradar360.com/article/development-and-validation-of-a-reverse-phase-high-performance-liquid-chromatogr-ec3e92366fb1a9cePharmaRadar360en2026-09-19T00:00:00.000ZDevelopment and Validation of A Reverse Phase High Performance Liquid Chromatography (Rp-Hplc) Method for The Estimation of Process Related Impurity from Lobeglitazone Sulfatehttps://www.pharmaradar360.com/article/citrate-versus-heparin-anticoagulation-during-crrt-with-mg350-hemoadsorption-in-fd82283ab4495bfcPharmaRadar360en2026-09-19T00:00:00.000ZCitrate versus heparin anticoagulation during CRRT with MG350 hemoadsorption in critically ill patients: a randomized controlled trial protocolhttps://www.pharmaradar360.com/article/clinical-profile-and-treatment-outcomes-of-pleural-effusion-and-empyema-thoracis-bbe452d5da9517d3PharmaRadar360en2026-09-19T00:00:00.000ZClinical Profile and Treatment Outcomes of Pleural Effusion and Empyema Thoracis in a Tertiary Hospital of Bangladeshhttps://www.pharmaradar360.com/article/factors-associated-with-lymphoma-recurrence-following-autologous-stem-cell-trans-bcec6940d14004dbPharmaRadar360en2026-09-19T00:00:00.000ZFactors Associated with Lymphoma Recurrence Following Autologous Stem Cell Transplantationhttps://www.pharmaradar360.com/article/phytochemical-dark-matter-unlocking-the-untapped-chemical-diversity-of-medicinal-341f859e1c659ac5PharmaRadar360en2026-09-19T00:00:00.000ZPhytochemical dark matter: unlocking the untapped chemical diversity of medicinal plantshttps://www.pharmaradar360.com/article/oroxylin-a-loaded-microemulsion-gel-a-promising-approach-for-anti-gout-therapy-a-7d7fc2b7ca4b7e5bPharmaRadar360en2026-09-19T00:00:00.000ZOroxylin A- loaded microemulsion gel: a promising approach for anti-gout therapy- a reviewhttps://www.pharmaradar360.com/article/plant-protein-microcapsules-for-nutraceutical-delivery-3b5fb647884c6359PharmaRadar360en2026-09-19T00:00:00.000ZPlant protein microcapsules for nutraceutical deliveryhttps://www.pharmaradar360.com/article/quality-control-evaluation-of-different-brands-of-paracetamol-tablets-available-c006a743158b4b8cPharmaRadar360en2026-09-19T00:00:00.000ZQuality control evaluation of different brands of paracetamol tablets available in the local market of Rohtakhttps://www.pharmaradar360.com/article/clinical-correlation-between-the-severity-of-periodontitis-and-alzheimer-s-disea-48dd87cd72f1219bPharmaRadar360en2026-09-19T00:00:00.000ZClinical correlation between the severity of periodontitis and Alzheimer’s disease, along with neuropsychiatric symptoms in the rural populationhttps://www.pharmaradar360.com/article/predicting-hemorrhagic-transformation-in-acute-ischemic-stroke-using-a-machine-l-38c2eae679ddb40bPharmaRadar360en2026-09-19T00:00:00.000ZPredicting hemorrhagic transformation in acute ischemic stroke using a machine learning model based on clinical and HR-MRI featureshttps://www.pharmaradar360.com/article/effects-of-adding-gait-retraining-with-visual-feedback-to-resistance-balance-tra-1e167cbe3a805226PharmaRadar360en2026-09-19T00:00:00.000ZEffects of adding gait retraining with visual feedback to resistance-balance training on kinematics, centers of pressure, and proprioception in individuals with chronic ankle instability: a randomized controlled trialhttps://www.pharmaradar360.com/article/low-intensity-transcranial-electrical-stimulation-for-schizophrenia-a-triple-bli-e89af31c21e6c675PharmaRadar360en2026-09-19T00:00:00.000ZLow intensity transcranial electrical stimulation for schizophrenia: a triple-blind, randomized, sham-controlled multicenter trial (STIM’Zo)https://www.pharmaradar360.com/article/clinical-indications-and-determinants-of-field-of-view-selection-in-cone-beam-co-502e081a3fdf5538PharmaRadar360en2026-09-19T00:00:00.000ZClinical indications and determinants of field-of-view selection in cone-beam computed tomography among pediatric patients: a two-center cross-sectional study